SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Roller coaster with carts falling speed motion blur down and screaming people against the background of Ferris wheel in amusement park sunset sky clouds
Tariffs
Biotech’s ‘Nauseating Roller Coaster’ Repels Investors
Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty sent fresh shockwaves through an already fragile market.
April 23, 2025
 · 
5 min read
 · 
Ana Mulero
Business people and concepts vector art exit
C-suite
Stoffels To Depart Galapagos, Short of Five-Year Mission To Remake the Biotech
Paul Stoffels left his perch as J&J’s chief scientific officer in 2022 to replace Galapagos’ founding CEO Onno van de Stolpe, inheriting a company that had suffered a series of clinical failures since its 1999 creation.
April 22, 2025
 · 
2 min read
 · 
Annalee Armstrong
Engraving human heart illustration set isolated on black background with CMYK color
Cardiovascular disease
Pfizer Mounts Defense of Cardiac Blockbuster as Alnylam, BridgeBio Enter Market
Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.
April 22, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Concept 3d illustration of a collocated containers as though a computer game due to imports tariffs.
Manufacturing
Roche, Regeneron Pledge Multibillion Boosts to US Manufacturing as Trump’s Tariffs Loom
Roche is committing $50 billion while Regeneron inked a $3 billion manufacturing deal with Fujifilm, allowing the pharma to “nearly double” its U.S. large-scale manufacturing capacity.
April 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Gilead's headquarters in Silicon Valley
Breast cancer
Gilead’s Trodelvy, With Keytruda, Slows Disease Progression in Triple-Negative Breast Cancer
Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in metastatic triple-negative breast cancer, according to analysts at Truist Securities.
April 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Breast Cancer awareness month card illustration. Pink ribbon and hand fist up power in retro collage craft style. Design concept for disease prevention or october support campaign.
Breast cancer
AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data
Analysts at Leerink Partners said in a Monday note that DESTINY-Breast09’s findings “could support an approval” for Enhertu in first-line HER2+ metastatic breast cancer.
April 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk advertising flags and logo on facade
Obesity
Novo Seeks FDA Nod for Semaglutide Pill as Oral Obesity Space Heats Up
Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according to a company spokesperson.
April 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Concept business people work with modern laptop. Double exposure. Meeting room in office building background
FDA
Banning Industry From FDA Adcomms Won’t ‘Move the Needle Much’ in Makary, RFK’s Fight Against COIs
FDA Commissioner Marty Makary last week announced a directive that would limit industry participation in the agency’s advisory committees. But not only do company reps serve only as non-voting members, a 1997 law actually requires industry involvement.
April 21, 2025
 · 
5 min read
 · 
Heather McKenzie
command failed. Business team walk in a line following faulty orders vector
Layoffs
Tempest Cuts 80% of Staff While Considering Strategic Alternatives
California-based Tempest Therapeutics is laying off 21 of its 26 full-time employees. The cuts come while the biotech is exploring strategic alternatives, including a merger or acquisition, as it tries to move its investigational PPARα antagonist into late-stage development.
April 21, 2025
 · 
1 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS